<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04197596</url>
  </required_header>
  <id_info>
    <org_study_id>NYMC 590</org_study_id>
    <nct_id>NCT04197596</nct_id>
  </id_info>
  <brief_title>Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs)</brief_title>
  <official_title>A Pilot Study in the Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs) in Children, Adolescents and Young Adult Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nationwide Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>New York Medical College</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      BK cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture&#xD;
      System will be safe and effective in decreasing specific viral load in children, adolescents&#xD;
      and young adults (CAYA) with refractory BK infection post Allogeneic Hematopoietic Stem Cell&#xD;
      Transplantation (AlloHSCT) or with primary immunodeficiencies (PID).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>12 weeks</time_frame>
    <description>Patients will be monitored for adverse events following each CTL infusion</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Viral Infection</condition>
  <condition>Primary Immune Deficiency Disorder</condition>
  <arm_group>
    <arm_group_label>BK CTL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients with refractory BK infection will receive up to 5 infusions of BK CTLs that are donor derived.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BK CTL</intervention_name>
    <description>Patient with refractory BK infection and a HLA Matched Related Donors: BK specific CTLs (2.5 x 104 CD3/kg) infused intravenously on day 0 and may be additionally reinfused at a minimum of every two weeks (depending on safety and efficacy) for a maximum of five total infusions (maximum 12.5 x 104 CD3/kg).&#xD;
Patients with refractory BK virus and a HLA Mismatched Related Donors: BK specific CTLs (0.5x104 CD3/kg) infused intravenously on day 0 and may additionally be reinfused at a minimum of every two weeks (depending on safety and efficacy) for a maximum of five total infusions (maximum 2.5 x 104 CD3/kg).</description>
    <arm_group_label>BK CTL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        .1.1 Patients with refractory BK infection post allogeneic HSCT, post solid organ&#xD;
        transplantation or with primary immunodeficiencies with either&#xD;
&#xD;
          -  Increasing urine and/or plasma BK RT-PCR DNA (by 1 log) after 7 days or persistent&#xD;
             quantitative qRT-PCR DNA copies after 14 days despite two weeks of appropriate&#xD;
             anti-viral therapy AND/OR&#xD;
&#xD;
          -  Medical intolerance to anti-viral therapies including:&#xD;
&#xD;
               -  2 renal toxicity with cidofovir or other &gt; grade 2 toxicities secondary to&#xD;
                  cidofovir And/or&#xD;
&#xD;
          -  known resistance to cidofovir 1.2. Consent: Written informed consent given (by patient&#xD;
             or legal representative) prior to any study-related procedures.&#xD;
&#xD;
        1.3 Performance Status &gt; 30% (Lansky &lt; 16 yrs and Karnofsky &gt; 16 yrs) 1.4 Age: 0.1 to 30.99&#xD;
        years 1.5 Females of childbearing potential with a negative urine pregnancy test&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
          1. Patient with acute GVHD &gt; grade 2 or extensive chronic GVHD at the time of BK CTL&#xD;
             infusion&#xD;
&#xD;
          2. Patient receiving steroids (&gt;0.5 mg/kg prednisone equivalent) at the time of BK CTL&#xD;
             infusion&#xD;
&#xD;
          3. Patient treated with donor lymphocyte infusion (DLI) within 4 weeks prior to BK CTL&#xD;
             infusion&#xD;
&#xD;
          4. Thymoglobulin (ATG) or Alemtuzumab within 30 days&#xD;
&#xD;
          5. Patient with poor performance status determined by Karnofsky (patients &gt;16 years) or&#xD;
             Lansky (patients ≤16 years) score ≤30%&#xD;
&#xD;
          6. Concomitant enrollment in another experimental clinical trial investigating the&#xD;
             treatment of refractory BK infection.&#xD;
&#xD;
          7. Any medical condition which could compromise participation in the study according to&#xD;
             the investigator's assessment&#xD;
&#xD;
          8. Known HIV infection&#xD;
&#xD;
          9. Female patient of childbearing age who is pregnant or breast-feeding or not willing to&#xD;
             use an effective method of birth control during study treatment.&#xD;
&#xD;
         10. Known hypersensitivity to iron dextran&#xD;
&#xD;
         11. Patients unwilling or unable to comply with the protocol or unable to give informed&#xD;
             consent.&#xD;
&#xD;
         12. Known human anti-mouse antibodies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchell S Cairo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mitchell S Cairo, MD</last_name>
    <phone>9145942150</phone>
    <email>mitchell_cairo@nymc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lauren Harrison</last_name>
    <phone>16172857844</phone>
    <email>lauren_harrison@nymc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Chu, MD</last_name>
      <email>Julia.Chu2@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kenneth Cooke, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchell S Cairo, MD</last_name>
      <phone>914-594-2150</phone>
      <email>mitchell_cairo@nymc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lauren Harrison, RN</last_name>
      <phone>6172857844</phone>
      <email>lauren_harrison@nymc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mitchell S. Cairo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hosptial</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dean Lee, MD, PhD</last_name>
      <phone>614-722-3550</phone>
      <email>Dean.Lee@nationwidechildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nancy Bunin, MD</last_name>
      <phone>215-590-2255</phone>
      <email>buninn@email.chop.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julie A Talano, MD</last_name>
      <phone>414-955-4185</phone>
      <email>jtalano@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Julie A Talano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 11, 2019</study_first_submitted>
  <study_first_submitted_qc>December 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>February 19, 2021</last_update_submitted>
  <last_update_submitted_qc>February 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Primary Immunodeficiency Diseases</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

